The costs of health care in the last year of life are a subject of debate and myth. Expensive interventions at the end of life often are blamed for the rapid increase in health care spending, but evidence about the existence of such exceptionally high expenditures at the end of life is rare and faulty. This investigation examines the development and composition of health care costs at the end of life for all age groups in The Netherlands. In contrast with earlier studies, this research analyzes both acute care (cure) and long-term care (care) costs. As an alternative for the frequently used concept of calendar years, we employed the concept of life years for calculating the costs at the end of life. We found that when life approaches its end, health care expenditures indeed rise sharply, especially in the last months. However, when we compared total cure costs in the last year of life to the total cure costs for the entire population, we concluded that the end-of-life share was only about 10%. Results of this study show that interventions to reduce costs in the last year of life will have only a modest impact compared to the total health care budget. Tom Stooker, M.Sc., and Joost W. van Acht, M.Sc., are both economists; Ben A. van Hout, Ph.D. , is a professor of econometrics; and Jan J. V. Busschbach, Ph.D., is a psychologist, all at
It is often remarked that the costs of medical care are rising fast because of the intensive and complex technical medical treatment employed in the last stage of life (Chambers et al. 1994; Pallone 1992; Scitovsky 1994) . The phenomenon of continuously rising health care budgets has forced policymakers to find ways to control the increase in health care costs and to keep the health care system affordable. The idea that costs are concentrated at the end of life provides a tempting target for policymakers to aim cost-reduction programs. It is often thought that since people at this stage will die anyway, these cost reductions will have only limited harmful effects.
Since 1993, the Dutch social health insurance sys-tem has undergone major reforms. The competing sickness funds, the Dutch equivalent of public health insurance, receive risk-adjusted capitation payments based on age, gender, region, and a disability indicator. Because these crude health indicators do not reflect expected costs accurately, an extensive ex post equalization occurs among sickness funds. Mortality has been suggested as an additional risk adjuster, mainly because of the assumption of high health care expenditures before death. If the costs in the period immediately preceding death are indeed high, then mortality can be a promising risk adjuster in capitation payment schemes for health plans. The supposed high costs in the last year of life also play a role in the discussion on euthanasia. According to the stereotypical line of thought, a positive attitude toward euthanasia assumes a substantial reduction in health care costs. It is difficult to say whether advocates of a liberal standpoint on euthanasia are convinced by this cost argument. On the other hand, one could say that the cost-saving argument plays a significant role in this discussion only if the costs at the end of life are indeed high. If the costs turn out to be low, the discussion about euthanasia will be freed from this disturbing argument (Emanuel and Battin 1998) .
There is conflicting evidence on the absolute magnitude of the cost of health care during the last year of life. Emanuel (1996) and Emanuel and Emanuel (1994) give estimates that range from 10% to 45% of total health care expenditures. Lubitz and Riley (1993) examined the trend in Medicare payments in the last year of life and concluded that for people age 65 or older costs in the last year of life were 27% of total Medicare payments. This percentage was stable during the period 1976-1988. This study also showed that within the last year of life, health care costs increase dramatically. Their results, however, are only valid for the aged Medicare population.
In The Netherlands, no specific articles exist that are devoted primarily to the subject of cost during the last period of life. There are, however, some related studies done by Nooren and van Vliet (1994) and van Vliet and Lamers (1998) . Both studies show the development of the cure costs in the last calendar year of life but not in the last actual year of life (i.e., the last 365 days before a person dies). Furthermore, these studies are limited to the so-called ''cure costs'' and do not incorporate costs of long-term care. In addition, these studies concentrate on the development of costs on an annual basis. Costs on a monthly basis are not examined.
In this investigation, we have tried to improve the estimates with respect to the extent and composition of health care costs in the last period of life. This study examines both cure (acute care) costs and care (long-term care) costs for all age groups in The Netherlands. Clarifying the composition and extent of health care costs in the last year of life can make policymakers more aware of the allocation of health care costs, and subsequently guide them in targeting cost-reduction programs.
Data
In this study, we distinguish between health care expenditures for ''cure'' and ''care.'' The cure expen-ditures are estimated using data from the Dutch Sickness Fund Act (Ziekenfondswet or ZFW). In The Netherlands, employees (and their families) earning an annual wage below $30,000 US are insured compulsorily with one of the public sickness funds. About two-thirds of the Dutch population are insured in this way. The remainder of the population is insured in the private health insurance sector. Both the private health insurance companies and the sickness funds provide coverage mainly for ''noncatastrophic risks'' (so-called short-term acute care) such as hospital care and physician services. The costs of prescribed drugs could not be included in the data.
We estimate care expenditures in this study in relation to the ''Exceptional Medical Expenses Act'' (de Algemene Wet Bijzondere Ziektekosten or AWBZ). The AWBZ provides coverage for the entire Dutch population mainly against catastrophic risks (so-called long-term care). This includes primarily nursing home care, institutional psychiatric services, and institutional care for mentally handicapped people. The AWBZ expenditure can be subdivided into intramural, semimural, and extramural expenditures. Intramural and semimural expenditures are for care provided by the institutions where patients actually live. Extramural expenditures are for care provided to people who still live on their own. These extramural expenditures mainly consist of forms of home care and outpatient mental health care. The data used in this study only include the intramural and semimural expenditures, which comprise about 80% of the total AWBZ expenditures.
The data set used in this study consists of a sample of approximately 85,000 enrollees from one Dutch sickness fund. The sickness fund's original file contained data on approximately 450,000 individuals over the period 1988 through June 1993. Compared to the average population covered by Dutch sickness funds, the enrollees used in this study include a slight overrepresentation of people in nursing homes and a slight underrepresentation of people in mental institutions (van Barneveld, van Vliet, and van de Ven 1997) . This insurance file included both individuals who received health care services and people who did not.
In creating the data set, we gave priority to establishing a homogeneous sample with respect to changing regulations and administration. The data set for the 85,000 enrollees was obtained in two steps. First, we included in the sample all members who lived in an AWBZ institution on January 1, 1993. Approximately 5,500 members met this criterion. We re-ceived the annual care (AWBZ) costs for these people for the period 1988 through June 30, 1993, as well as their cure (ZFW) costs for the period 1990 through June 1993. For the second step, we took a random sample of about 80,000 members who were insured at the sickness fund on January 1, 1990. We received cure costs for these people for the period 1990 through June 1993. Combining members from the first and second steps, and eliminating any overlap, gave us a data set of 84,734 members who were either insured on January 1, 1990, or living in an AWBZ institution on January 1, 1993. Of these members, 2,506 died in the period 1990 through the first half of 1993.
Because the data set was created in such a way that AWBZ patients were overrepresented, we had to assign weights to each fund member to correct for this overrepresentation. The weight of AWBZ patients included in the first step was set equal to 1 and the weight of other members to 5.61. 1 Thus, the weighted percentage of AWBZ patients in the data set is about 1.22%, which was the real percentage of AWBZ patients in the sickness fund in 1993, and was also representative for the Dutch sickness fund population. All results presented in this study use this weighting to correct for the overrepresentation of AWBZ patients.
Only Dutch sickness fund members are included in our data set. Privately insured individuals are younger, healthier and more likely to be men than sickness fund members. As a result, the health care expenditures for both care and cure are lower for privately insured individuals. However, there is no reason to assume that the costs in the last year of life as a fraction of all expenditures during life are very different for privately insured individuals than for sickness fund members.
The data file used in this study has been described by van Barneveld, van Vliet, and van de Ven (1997) . It contains health care expenditures and demographic information on an individual level. For people who died, the date of death was registered. However, we limited our analysis of the care data to a yearly level and omitted information about dates of death for AWBZ patients. We did this because the monthly distribution of registered deaths within the AWBZ group showed a highly irregular pattern, which likely was due to some deficiency in the administration process.
Methodology
The working file that we created consisted of all people who died in the period 1990 through June 1993, and contained information on 2,506 individuals. Two different methods were employed to show the development of the health care costs in the last years of life: the ''conventional method'' and the ''life-year method.'' The first method has been used frequently by other researchers (e.g., van Vliet and Lamers 1997) . However, in our opinion, the latter method yields a better indication of the costs in the last year of life.
Conventional Method
The conventional method calculates costs per calendar year. Only the costs of a person who died on December 31 can be considered complete. People who died before December 31 of a year incurred costs for less than a year. Thus to calculate the average costs for a person in the last calendar year of life, a correction factor is estimated for the limited duration of the year. The common method to calculate this correction factor is: 365/number of life days in the last calendar year. In our data set, this resulted in an average correction factor of 1.83. Another common method is to use the theoretical value 2. This method is used in cases where the data do not allow for the previous calculation.
Although the method described provides a good estimate of the average costs in the last calendar year of life-that is, when a person dies on December 31-it overestimates the average costs in the actual last 365 days before a person's death. That is the case because the last months of life are also the most expensive: when a person dies halfway through the last calendar year, the most expensive months occurred all in that half year. Thus, when these expensive months are multiplied with the correction factor, the costs in the last year of life are overestimated.
Life-Year Method
In this study, we suggest another method to overcome the problem of overestimation of the costs in the last . The data set contains information up to three years before the year of death, which therefore limits our analysis to two life years before death. Given the deficiencies in the registration of the date of death in the AWBZ patient group, this methodology can be applied only to cure costs and cannot be applied for care costs. Thus, we do not include care costs in our life-year calculations of costs.
Developments in Months
In our analysis, we also look at the pattern of costs on a monthly basis. Since the data set contained aggregated cost data per calendar year, we had to take a number of steps to calculate monthly costs. We know that the costs in the last calendar year of life for a person who dies in January can be attributed to the person's last month of life. The average costs for the last two months of life can be calculated in the same fashion by taking the costs of those who die in February. We used this method to calculate the costs at a cumulative monthly level. In this case, ''cumulative monthly costs of the second month'' means the average costs of the first month plus the second month. The date of death was used to correct the costs for all the months, taking into account the different number of days in each month. This gave us the average costs of people up until their last two, three, and finally 12 months of life.
However, we were interested in the costs for each specific month before death. To calculate the costs, for instance, of the second month before death, we subtracted the average cumulative costs of the last month of life from the average cumulative costs of the last two months of life. This meant that we could subtract the average cumulative costs of people who died in January (corrected to entire months) from the average cumulative costs of people who died in February. The method used for calculating the costs of the third until the 12th month of life followed the same logic. Again, given the deficiencies in the registration of the date of death in the AWBZ patients group, this methodology was not applied to the care costs.
As noted earlier, the data set suffers from a slightly uneven distribution in the date of death: some months contain relatively few individuals. We applied standard regression analysis, performed on the cumula-tive monthly level, to smooth out this random variation in the data.
Results

Cost Developments in Years
The analyses according to the conventional method showed a sharply increasing trend for both cure and care costs. The average cure costs per person per calendar year increased from 4,365 Dfl ($2,180 US) in the third year before the moment of death to 20,000 Dfl ($10,000 US) in the final year. The increase of the cure costs in the last year compared to the preceding year was approximately 170% (see Figure 1) .
The care costs showed a relatively smaller increase and represent a smaller share of the total costs in the last calendar year. The average care costs per person in the last calendar year of life amounted to 3,100 Dfl ($1,600 US). These costs comprised approximately 13% of the total costs (care ϩ cure) in the last calendar year of life. A comparison of the last calendar year with the preceding year showed an increase of 130% in care costs.
If the life-year method is indeed correct, the conventional method leads to a serious overestimation of the costs in the last year of life ( Figure 2 ). Average cure costs in the last L-year of life amounted to 15, 165 Dfl ($7, 580 US) . This is approximately 30% lower than cure costs estimated by the conventional method. Moreover, the life-year method showed a relatively sharper increase in cure costs in the last year of lifeabout 182%-compared to the preceding year. Figure 3 shows an overview of the development of the cure costs in the last 13 months of life. Due to a slightly uneven distribution of the dates of death in the data file (discussed earlier), the monthly cost estimates for seven to 12 months before death were less than the average costs per month of the preceding year. Thus, it is clear that the estimates for months seven to 12 are not applicable. 3 Our estimates of the costs per month clearly showed an increasing trend: 36.5% of the costs in the last life year are incurred in the last month of life.
Cost Developments in Months
Conclusion and Discussion
This investigation shows that costs in the last stage of life rise dramatically. The life-year method of calculation demonstrates that costs rise relatively more steeply than when the conventional calendar-year method is used. Because costs appear to increase sharply, the conventional method is likely to lead to an overestimation of the costs in the last year of life. The results show that, if the life-year method is correct, the conventional method overestimates costs by about 30%. We also found that compared to the cure costs, the care costs in the last year of life are a small part of the total costs.
How large are the total costs in the last year of life compared to the total expenditures on health care? Previous estimates of health care costs in the last year of life have ranged from 10% to 45% of total health care costs (Emanuel 1996; Emanuel and Emanuel 1994) . When we compared the total cure costs in a person's last life year to the total cure costs for the 1997b) , we concluded that this share (cure costs for last life year/total cure costs) was approximately 10%. The same ratio for the care costs showed that the care costs for the last year of life comprised approximately 5% of the total care expenditure. The interpretation of these ratios, however, is somewhat complicated because the CBS uses a slightly different definition of the terms cure and care.
How is it possible that costs in the last year of life are lower than generally assumed? Obviously, the picture of an expensive, high-tech battle against death dominates our image of health care. Indeed, we found a number of such examples in our database. However, the database also showed that most of us will die without such a struggle and thus without the expense. In reality, health care is dominated by day-today routine care and cure services for those in need. Although less heroic than life-saving efforts, the dayto-day care and cure services seem to be the major cost drivers of the health care budget. In other words, our results suggest that it is not the costs of dying, but the costs of living that are the major force behind the rising costs in health care.
Limitations of this Study
The life-year method enabled us to look at the development of costs in life years instead of in calendar years. However, due to the uneven distribution of the care, it was not possible to analyze the care costs using this new method. We also were not able to look at the development of the care costs on a monthly basis. These problems could be solved if the agencies would use better ways to register their patient data. To achieve a clearer picture of care costs, in particular, it is necessary to use a data file where the date of death is registered precisely.
The definitions of the so-called ''cure'' and ''care'' costs used in this study are somewhat arbitrary. We recognize that the cure costs contain some elements of care and that the care costs contain some elements of cure. We consider, however, that it is not correct to ignore or eliminate the care costs as has been done in other studies (e.g., Lubitz and Riley 1993) ; the care component plays a substantial role in the total costs of medical services.
In comparison with previous studies, our data set included health care expenditures for many types of care. However, even our extensive data set omitted some health care expenditures, such as those for prescribed drugs and some forms of home care. Further research in this area should focus on collecting all relevant expenditure data. This information was not available for the years on which our study was based.
The insurance data file contains only people who were insured by one of the sickness funds. It is commonly known that privately insured people have a better health status than those who are insured by a sickness fund (van Vliet and van de Ven 1986; Mackenbach 1991) . Obviously, a more representative picture of total health care spending could be obtained by including people who are privately insured.
As our study shows, only a small amount of costs can be attributed to the last period of life. Further research focused on the composition of health care costs in the remaining part of one's life would be useful.
Policy Implications
At the start of our research, we speculated as to what the impact of our results would be on the ongoing discussion about euthanasia. A commonly heard argument in the debate about euthanasia relates to cost saving. During our investigation, there was growing awareness that euthanasia reduces life by only a few days on average. Therefore, the cost-saving argument cannot be of great interest for society. The results of our study only strengthen this conclusion: in general, costs at the end of life are small compared to total lifetime costs for health care.
The sharp rising costs in the period immediately preceding death seem to suggest that mortality could be a promising risk adjuster in capitation payment schemes for health plans. On the other hand, the magnitude of the costs in a person's last year of life seem relatively low compared to the total lifetime costs. This suggests that risk adjustment on the basis of mortality will have only a modest effect. This idea was confirmed recently in a study by van Vliet and Lamers (1998) . They concluded that mortality would improve capitation payments marginally, at best. Thus, our present study reinforces their conclusions.
Discussions about how to keep medical services affordable in the future often consider interventions in the last year of life. However, to discuss these matters in a rational way, it is necessary to gain a clearer picture of the cost structure in the health care sector. This article shows that costs in the last year of life rise steeply. However, the increase in costs starts too late to influence the total share of costs in the last year of life dramatically. Since costs in the last year of life comprise only about 10% of total health expenditures, any intervention to reduce those costs will have only a modest effect on the health care budget. It may be worthwhile for policymakers to focus on the remaining 90% of costs incurred during the rest of a person's life.
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1 To calculate the weight factor, we assumed that the original insurance data file had a representative distribution of AWBZ and non-AWBZ patients (van Barneveld, van Vliet, and van de Ven 1997) . The insurance data file contained in total 450,000 individuals of whom 5,500 were hospitalized in an AWBZ institution on January 1, 1993. The sample from the insurance data file contained a total of 84,734 individuals of whom 5,500 were hos-pitalized in an AWBZ institution. This resulted in a weight factor for non-AWBZ patients of 5 
